A new vaccine using the same mRNA technology as the Pfizer jab against COVID-19 could be a breakthrough in the fight against pancreatic cancer.
In a promising early study conducted by German company BioNTech — which partnered with Pfizer to develop the lifesaving COVID shot — half of the patients remained cancer-free 18 months after having their tumors removed and receiving the jabs.
The groundbreaking trial — led by Dr. Vinod Balachandran at the Memorial Sloan Kettering Cancer Center in Manhattan — presented its promising results at the American Society of Clinical Oncology conference in Chicago on Sunday.
Doctors said the results showed that the vaccine could train the immune system to kill pancreatic cancer cells by boosting immune cells that target tumors.
#cancer #vaccines #cures
The New York Post is your source for breaking news, news about New York, sports, business, entertainment, opinion, real estate, culture, fashion, and more.
Subscribe to New York Post Sports: https://www.youtube.com/c/nypostsports
Catch the latest news here: https://nypost.com/
Follow The New York Post on:
Twitter – https://twitter.com/nypost
Facebook – https://www.facebook.com/NYPost